• Special Issue Topic
    Endocrine Resistant Breast Cancer
    Submission Deadline: October 31, 2021

    Guest Editors

    Dr. Simon Langdon E-Mail

    Reader, School of Medicine, University of Edinburgh, Edinburgh, UK

    Research Keywords: ovarian cancer; breast cancer; estrogen signaling; HER signaling; DNA repair


    Dr. Valerie Speirs E-Mail

    Professor and Chair in Molecular Oncology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK

    Research Keywords: oestrogen receptor biology; endocrine resistant breast cancer; male breast cancer; in vitro models; biomarker


    About the Special Issue

    The majority of breast cancers are estrogen receptor alpha (ERa) positive and most will initially respond to endocrine therapy. Current therapies to treat ERa-positive disease include aromatase inhibitors, selective estrogen receptor modulators (SERMs) and selective estrogen down-regulators (SERDs). However, resistance to these treatments will develop in many cancers and can be present either at the outset (de novo resistance) or develop on treatment (acquired resistance). Experimental and clinical investigations have demonstrated multiple mechanisms that can give rise to resistance and a range of therapeutic agents such as CDK4/6 inhibitors and other signalling inhibitors have been developed to circumvent these. Resistance mechanisms include changes in ER status (e.g. loss and mutation) and the involvement of compensatory pathways bypassing the dependence on estrogen activation particularly growth factor activation.

    In this issue, we welcome Reviews and Original Articles encompassing experimental laboratory research studies of endocrine resistance through to clinical investigations in breast cancer.

    Keywords: Breast cancer; resistance; endocrine; estrogen

    Call for Papers

    Published Articles

    Open Access
    Review
    Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
    Adjuvant hormonal therapy is one of the most important treatments of hormone-receptor-positive breast cancer and includes selective estrogen receptor modulators, aromatase inhibitors, and luteinizin...
    Alfredo Rossi ... Marta Carlesimo
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:490-495
    DOI: https://doi.org/10.37349/etat.2021.00059
    View:267
    Download:20
    Times Cited: 0
    Open Access
    Review
    Role of estrogen receptor coregulators in endocrine resistant breast cancer
    Breast cancer (BC) is the most ubiquitous cancer in women. Approximately 70–80% of BC diagnoses are positive for estrogen receptor (ER) alpha (ERα). The steroid ho...
    Kristin A. Altwegg, Ratna K. Vadlamudi
    Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:385-400
    DOI: https://doi.org/10.37349/etat.2021.00052
    View:805
    Download:59
    Times Cited: 0